<DOC>
	<DOCNO>NCT01388127</DOCNO>
	<brief_summary>The investigator perform double blind control study investigate efficacy oral administration 200 mg minocycline , neurological functional outcome acute hemorrhagic stroke effect blood brain barrier permeability .</brief_summary>
	<brief_title>Minocycline Treatment Acute Hemorrhagic Stroke</brief_title>
	<detailed_description>Minocycline , semisynthetic second generation derivative tetracycline , show clear beneficial neuroprotective effect animal model multiple sclerosis , Parkinson 's disease , Huntington 's disease amyotrophic lateral sclerosis . Animal model provide promise evidence minocycline 's ability improve outcome animal stroke model . In light finding , perform double blind control study investigate efficacy oral administration 200 mg minocycline , neurological functional outcome acute hemorrhagic stroke effect blood brain barrier permeability .</detailed_description>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Patients acute hemorrhagic stroke 1. age &gt; 18 2 . NIHSS score &gt; 5 3. onset stroke 6 24 hour prior begin treatment . Patients , arrive within 0 6 hour post stroke , treat medication accord best accept medical treatment guideline . 1 . Evidence disease central nervous system , include brain tumor , demyelinate disease , inflammatory disease central nervous system , craniotomy past , severe brain injury benign intracranial hypertension 2. preexist neurological disability 3. know allergic response tetracycline 4. acute chronic renal failure 5. preexisting infectious disease require antibiotic therapy 6. swallowing difficulty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>